Latest 340B ruling delivers blow to providers
Healthcare
Stay updated with breaking news from Beth Feldpush. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers. At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program. The U.S. Court of Appeals for the District of Columbia has said that they can. The May 21 ruling issued by Circuit Court Judge Gregory Katsas found for Novartis Pharmaceuticals
Denver Health officials, Colorado lawmakers, health care experts and city officials spoke about the city’s safety-net hospital financial predicament, what could happen if it failed and what it would take to stabilize the health system.
CMS finalized a $9 billion lump sum payment to 1,700 hospitals participating in the 340B Drug Pricing Program to make them whole from unlawful payment cuts from 2018 to 2022.
With an average operating margin of −8.6 percent, charity care and other uncompensated care leaves America's essential hospitals deep in the red.